-
Drugs
-
Resources for You
-
-
Zanamivir (marketed as Relenza) Information
Zanamivir is approved for treatment of acute uncomplicated illness due to influenza A and B in patients 7 years of age and older. It is also approved for preventive use (prophylaxis) in patients 5 years of age and older.
-
Related Information
- Relenza Letter for Emergency Use Authorization (PDF - 47KB)
- Relenza Healthcare Provider Fact Sheet (PDF - 30KB)
- Relenza Patient Fact Sheet (PDF - 28KB)
- Stockpiled Antivirals at or Nearing Expiration
- Relenza (zanamivir) Inhalation Powder Dear Healthcare Professional Letter October 2009 (PDF - 66KB)
- Relenza: Consumer Questions and Answers
-
-
Labeling and Regulatory History from Drugs@FDA
-
Contact Us
Human Drug Information
- (888) 463-6332
- (301) 796-3400
- druginfo@fda.hhs.gov
Division of Drug Information (CDER)
Office of Training and Communication
WO51-2201
10903 New Hampshire Avenue
Silver Spring, MD 20993
-
-
-